By Jennie Ritchie (NAMSA Global Associate Product Marketing Manager – QCSA Laboratory Services), Samantha Westgate (Former NAMSA Scientific Director, Microbiology and In Vitro Development) and Jim Pomonis (Former NAMSA Associate Vice President, Scientific Affairs)
Despite the advances in burn wound management, infection is a primary cause of morbidity, with infected burn wounds being responsible for 51% of burn related deaths. Because of the growing threat of multidrug resistant pathogens in burn injuries, novel therapeutic innovation remain important. This paper presents a comparison of common models and methods that support the development of novel burn wound antimicrobial treatments, of commonly available burn wound models 74% are performed in vivo, 23% are in vitro and just 3% use ex vivo tissue. The manufacturing of burn wound care products requires careful attention to materials, sterilisation, quality control, regulatory compliance and product design. By addressing these considerations systematically, manufacturers can successfully bring innovation solutions to the burn wound market while ensuring patient safety and product quality.
According to the World Health Organization (WHO), it is estimated that each year, approximately 11 million people suffer from burn wounds (Markiewicz-Gospodarek et al, 2022) and invasive infection is now the chief reason for death after burn injuries, with infected burn wounds being responsible for 51% of burn related deaths (Norbury et al, 2016). Despite advances in burn wound management, infection is a primary cause of morbidity in all age groups. One of the organisms responsible for infections in burn wounds is Pseudomonas aeruginosa, an opportunistic pathogen capable of infecting most tissues and commonly demonstrating low susceptibility to therapeutic modalities. Another organism of particular concern for burn patients is the multidrug resistant pathogen Staphylococcus aureus, which expresses an ability to excrete several protein exotoxins that can lead to additional complications. With the growing threat of multidrug resistant pathogens in burn injuries, novel therapeutic innovation remains important (Salyer et al, 2021).
How Can NAMSA Help?
When it comes to successful MedTech development studies, experience matters. NAMSA has amassed the largest breadth and depth of therapeutic expertise and knowledge across the continuum of microbiology and in vitro testing services. We have assisted with the successful research, development and commercialization of a wide range of wound healing devices. To learn more about our capabilities, visit: https://namsa.com/services/medical-device-testing/medical-device-microbiology-testing/.
Anney Peterson is the Senior Marketing Operations Specialist at NAMSA, focusing on expanding the overall knowledge and understanding in the MedTech industry. She obtained a BBA in Marketing from the University of Toledo (Ohio) as well as an A.S. in Psychology from Monroe County Community College (Michigan).